Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase I

Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase I

Funder: National Institutes of Health (NIH)

Description: This challenge aims to spur the development, validation, and dissemination of a publicly available suite of novel RNA-targeting technologies for new therapeutic classes that can lead to the development of precision RNA-targeted therapies.

Eligible Disease Categories

1. Diseases caused by difficult-to-drug protein targets (proteins unlikely to be modulated with a small molecule) that could be treated upstream at the RNA level 2. Diseases that are currently incurable but have roots in RNA dysfunction

Phase 1 Scope

• Participants will design an RNA-targeting therapeutic technology that can be elaborated into a working prototype in the second stage of the challenge
• Challenge is separated into three phases total

Award Amount

• $20,000 per winner
• Up to 25 winners